{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Safety+of+Elevated+Doses&page=3",
    "query": {
      "condition": "Pharmacokinetics and Safety of Elevated Doses",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 86,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Safety+of+Elevated+Doses&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Safety+of+Elevated+Doses&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T12:09:25.109Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03355066",
      "title": "A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "SM08502",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biosplice Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2017-11-06",
      "completion_date": "2022-11-14",
      "has_results": false,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 14 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03355066"
    },
    {
      "nct_id": "NCT05264493",
      "title": "Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "NaxRedy ™",
          "type": "DRUG"
        },
        {
          "name": "Naloxone Hydrochloride Injection, USP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 13,
      "start_date": "2020-10-06",
      "completion_date": "2021-01-08",
      "has_results": false,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05264493"
    },
    {
      "nct_id": "NCT07423598",
      "title": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD0780",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-02-24",
      "completion_date": "2026-06-29",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07423598"
    },
    {
      "nct_id": "NCT01742988",
      "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Relapsed Lymphoma",
        "Refractory Lymphoma",
        "Relapsed and/or Refractory Lymphoma",
        "Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)",
        "Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Double-hit Lymphoma (DHL)",
        "Triple-hit Lymphoma (THL)",
        "Double-expressor Lymphoma (DEL)",
        "High-grade B-cell Lymphoma (HGBL)"
      ],
      "interventions": [
        {
          "name": "fimepinostat",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Curis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2012-12",
      "completion_date": "2020-10-09",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01742988"
    },
    {
      "nct_id": "NCT07867340",
      "title": "A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "C-Reactive Protein"
      ],
      "interventions": [
        {
          "name": "LY5625573",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 96,
      "start_date": "2026-09",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 2,
      "location_summary": "Los Alamitos, California • Dallas, Texas",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07867340"
    },
    {
      "nct_id": "NCT03202992",
      "title": "Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HSIL, High-Grade Squamous Intraepithelial Lesions",
        "Human Papilloma Virus Infection",
        "HIV Infection",
        "Anal Cancer",
        "Anus Neoplasms"
      ],
      "interventions": [
        {
          "name": "ABI-1968",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Antiva Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "27 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "27 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2017-08-11",
      "completion_date": "2019-02-04",
      "has_results": false,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03202992"
    },
    {
      "nct_id": "NCT01413451",
      "title": "Amatuximab for High Mesothelin Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Carcinoma, Pancreatic Ductal",
        "Mesothelioma",
        "Ovarian Neoplasms",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Amatuximab (MORab-009)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 7,
      "start_date": "2011-07-12",
      "completion_date": "2013-11-15",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01413451"
    },
    {
      "nct_id": "NCT03928353",
      "title": "Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PB2452 Infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Sodium Chloride",
          "type": "DRUG"
        },
        {
          "name": "Ticagrelor Oral Tablet - Pre-Treatment",
          "type": "DRUG"
        },
        {
          "name": "Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SFJ Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2019-04-16",
      "completion_date": "2019-10-09",
      "has_results": true,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03928353"
    },
    {
      "nct_id": "NCT07477704",
      "title": "A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 420,
      "start_date": "2026-06-17",
      "completion_date": "2027-02-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 34,
      "location_summary": "Anniston, Alabama • Cullman, Alabama • Anaheim, California + 30 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07477704"
    },
    {
      "nct_id": "NCT04992273",
      "title": "COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "casirivimab+imdevimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "1 Minute to 12 Years"
      },
      "enrollment_count": 7,
      "start_date": "2021-09-13",
      "completion_date": "2022-06-01",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-12T12:09:25.109Z",
      "location_count": 7,
      "location_summary": "Anaheim, California • Miami, Florida • Stony Brook, New York + 4 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04992273"
    }
  ]
}